Omeros Corporation

OMER · Nasdaq · United States

Share price · OMER

$14.55-2.64 (-15.36%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.5M (2.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when OMER's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-16.5%
  2. 16 Oct 2026-13.8%
  3. 13 Aug 2026+26.5%
  4. 27 Jul 2026+15.8%

    Nothing announced by OMER that day or the session before.

  5. 6 Jul 2026+11.4%
  6. 29 Jun 2026+14.3%

    Nothing announced by OMER that day or the session before.

  7. 26 Jun 2026-19.1%
  8. 12 Jun 2026-14.2%

    Nothing announced by OMER that day or the session before.

  9. 27 Apr 2026+8.9%

    Nothing announced by OMER that day or the session before.

  10. 2 Apr 2026-9.8%

    Nothing announced by OMER that day or the session before.

Share of unusual movement by asset

For each asset, the share of OMER's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
narsoplimab(Yartemlea)
Approved
MASP-2Monoclonal antibody
Thrombotic Microangiopathy

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 October 2026Advisory committeenarsoplimabEMA confirms its recommendation to refuse marketing authorisation for Yartemlea (narsoplimab) after re-examination (CHMP negative opinion of 25 June 2026)
EU, EMA · European Medicines Agency · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$29M$14M$2.0M+ $130M short-term inv.—$4.2M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$9.9M$13M$1.9M+ $133M short-term inv.—-$15M operating cash flowreport ↗
2025-Q3—$16M$2.4M+ $34M short-term inv.$31M-$18M operating cash flowreport ↗
2025-Q2—$22M$1.9M+ $27M short-term inv.$25M-$22M operating cash flowreport ↗
2025-Q1$0$24M$4.3M+ $48M short-term inv.$33M-$36M operating cash flowreport ↗
2024-Q3—$24M$1.5M+ $122M short-term inv.$32M-$32M operating cash flowreport ↗
2024-Q2—$45M$2.1M+ $157M short-term inv.$56M-$46M operating cash flowreport ↗
2024-Q1—$27M$1.8M+ $229M short-term inv.$37M-$42M operating cash flowreport ↗
2023-Q3—$32M$31M+ $280M short-term inv.$38M-$33M operating cash flowreport ↗
2023-Q2—$30M$6.6M+ $335M short-term inv.$37M-$32M operating cash flowreport ↗
2023-Q1—$25M$3.8M+ $368M short-term inv.$34M$175M operating cash flowreport ↗
2022-Q3—$39M$146M+ $75M short-term inv.$17M-$26M operating cash flowreport ↗
2022-Q2—$24M$14M+ $108M short-term inv.$31M-$19M operating cash flowreport ↗
2022-Q1—$24M$9.0M+ $133M short-term inv.$33M-$15M operating cash flowreport ↗
2021-Q3$30M$27M$7.4M+ $43M short-term inv.$23M-$24M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$81M$9.7M+ $162M short-term inv.$0.8M-$116M operating cash flowreport ↗

For fiscal 2025, Omeros Corporation did not disclose revenue. R&D spend was $81.3M, down 32.0% YoY. The company reported cash and equivalents of $9.66M, a net loss of $3.35M, and a quarterly net burn of $3.35M.

Key reported events include FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA in December 2025, with commercial distribution beginning in January 2026, and a marketing authorization application under EMA review. In November 2025, Omeros closed an asset purchase and license agreement with Novo Nordisk for zaltenibart, receiving a $240.0M upfront payment with eligibility for up to $1.8B in milestones plus tiered royalties. Pipeline updates include planned Phase 2 trials in ARDS, preparation for OMS1029 Phase 2 development, a NIDA-funded OMS527 Phase 1b study, and ongoing IND-enabling work for OncotoX-AML.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$120M$3.4M+ $87M short-term inv.$39M-$149M operating cash flowreport ↗
2023-FY—$115M$7.1M+ $165M short-term inv.$29M$75M operating cash flowreport ↗
2022-FY—$113M$11M+ $184M short-term inv.—-$86M operating cash flowreport ↗
2021-FY—$119M$101M+ $56M short-term inv.—-$110M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 14 sales ($3.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-28Demopulos Gregory A MD · director, Chairman, CEO & PresidentAward / grant (derivative)500,000——Form 4
2026-09-23Borges David J. · VP, Finance & CAOOption exercise10,000$15.58$156KForm 4
2026-09-23Borges David J. · VP, Finance & CAOOpen-market sale10,000$20.95$210KForm 4
2026-09-23Borges David J. · VP, Finance & CAOOption exercise (derivative)10,000——Form 4
2026-09-22Borges David J. · VP, Finance & CAOOption exercise5,000$3.93$20KForm 4
2026-09-22Borges David J. · VP, Finance & CAOOption exercise5,000$2.94$15KForm 4
2026-09-22Borges David J. · VP, Finance & CAOOpen-market sale10,000$20.95$210KForm 4
2026-09-22Borges David J. · VP, Finance & CAOOption exercise (derivative)5,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 160 reporting institutions held 30.8M shares ($285.6M, 42.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.5,309,626$56.1M
2VANGUARD CAPITAL MANAGEMENT LLC2,983,259$31.5M
3UBS Group AG2,340,731$24.7M
4STATE STREET CORP1,919,575$20.3M
5STIFEL FINANCIAL CORP1,831,585$19.3M
6GEODE CAPITAL MANAGEMENT, LLC1,752,323$18.5M
7Corient Private Wealth LLC801,411$8.5M
8VANGUARD PORTFOLIO MANAGEMENT LLC718,675$7.6M
9CHARLES SCHWAB INVESTMENT MANAGEMENT INC582,512$6.2M
10BANK OF MONTREAL /CAN/568,426$6.0M
11NORTHERN TRUST CORP563,867$6.0M
12VANGUARD FIDUCIARY TRUST CO492,345$5.2M
13SUSQUEHANNA INTERNATIONAL GROUP, LLP485,030$5.1M
14MILLENNIUM MANAGEMENT LLC410,609$4.3M
15MORGAN STANLEY317,892$3.4M